KRAS and non-small cell lung carcinoma: Another study reported that the ULK1/2 inhibitor, DCC-3116, in combination with sotorasib, significantly reduced autophagic flux and showed synergy in KRAS-mutant NSCLC cells (Ghazi et al., 2024).